

- Bardet-Biedl syndrome, obesity and, 676
- Bariatric surgery
for obesity, 680-681, 680f
for type 2 diabetes, 667
- Barium enema, 393
- Barium radiography, dyspepsia and, 413
- Baroreflex loop, 21
- Barrett's esophagus, 389-390, 390f, 398, 598, 398.
e1f
- Bartonella henselae*, 844
skin and soft tissue infection from, 886
- Basal-bolus therapy, 661
- Basal energy expenditure (BEE), 684
- Basal ganglia, 1013, 1014f
Toxoplasma abscesses in, 862
- Basilar artery, 1035f, 1036
migraine associated with, 1058
- Basophils, 480, 515f, 516-517, 825
- Beer potomania syndrome, 300
- Behavior, major disorders of, 985-989, 987t
- Belatacept, 370
- Bence Jones protein, in multiple myeloma, 529
- Benign intracranial hypertension, 998
- Benign paroxysmal positional vertigo (BPPV),
1011, 1012f
- Benign prostatic hyperplasia, 719-723, 723t
- Benign scrotal diseases, 726-728
- Benzodiazepines
abuse of, 1129t-1130t, 1132
for alcohol withdrawal, 1133
for bipolar disorders, 986
for epilepsy, 1059
- Bernard-Soulier syndrome, 554t, 556
- Bernoulli equation, modified, 46
- Berylliosis, 235
- Beta-interferons (BIFNs), for multiple sclerosis,
1072
- Bevacizumab, 589-590, 590t
for non-small cell lung carcinoma, 270
- Bicarbonate
carbon dioxide transported as, 197
in chronic pancreatitis, 433
duodenal secretion of, 403
gastric secretion of, 403, 412
infusion of, in diabetic ketoacidosis, 669
in metabolic acidosis, 306, 306f
in metabolic alkalosis, 310
in respiratory acidosis, 312-313
in respiratory alkalosis, 311-312
- Bicarbonaturia, 310
- Bicuspid aortic valves
aortic coarctation and, 70
aortic stenosis and, 76
- Bifid scrotum, 654
- Bile acids, 469, 689
- Bile salt resin binders, 423
- Bile salts, malabsorption of
in Crohn's disease, 419
resin binders for, 423
- Bile stasis, 470
- Biliary and duodenal obstruction, 435
- Biliary colic, 472
- Biliary infection, initial empirical treatment of,
regimens used for, 891t
- Biliary neoplasms, 474. *see also*
Cholangiocarcinoma.
- Biliary obstruction, jaundice in, 444t, 448
- Biliary tract
disorders of, 473-475
acute cholangitis, 474
biliary neoplasms, 474
choledocholithiasis, 473-474, 473f
gallstone pancreatitis, 474, 474f
obstruction, 474
primary sclerosing cholangitis, 474-475, 475f
sphincter of Oddi, dysfunction of, 475
strictures, 474
inflammatory bowel disease and, 420
normal anatomy and physiology of, 469
- Bilirubin. *see also* Hyperbilirubinemia.
laboratory measurement of, 445
metabolism of, 444-445, 445f, 444.e1f
serum levels of, 441, 441t
normal, 444
- Binge drinker, 1126
- Binswanger's disease, 982-983
- Biologic response modifiers
for cancer, 590
for chronic inflammatory disorders, 12
- Biomarkers, of cancer, 585
- Bioprosthetic valves, for aortic stenosis, 77, 79f
- Biopsy, small intestine, in malabsorption, 381,
381t
- Biot respiration, 246
- Bipolar disorders, 985-987
- Bisferiens pulse, 29-30
- Bismuth subsalicylate, for diarrhea, 904
- Bisphosphonates
for hypercalcemia, 620
for osteoporosis prevention and treatment, 762
- Bivalirudin, in acute coronary syndrome, 102
- Biventricular pacing, for heart failure, 64
- Black pigment stones, 469
- Bladder cancer, 605-606
- Blast crisis, in CML, 494
- Bleeding, 544-563
abnormal, in women, 706-707, 706f
acute liver failure and, 457
caused by thrombocytopenia, 548-554
chronic kidney disease and, 366
clinical and laboratory evaluation of, 544-547,
544t, 545f-547f
coagulation factor disorders and, 545f, 559-561,
559.e1t
fibrinogen disorders and, 559-560
future prospectus for, 562
in liver disease, 560-561
major disease categories with, 545-547
with normal laboratory values, 561-562
platelet count and. *see* Thrombocytopenia
platelet destruction and, 550-554
with platelet function defects, 554-558, 554t,
555f. *see also* von Willebrand disease
vascular causes of, 547-548
- Bleeding time, 535, 544, 545f
- Bleomycin
pulmonary toxicity of, 231
scleroderma-like effects of, 791t
- Blinatumomab (BiTE), 500
- Blindness. *see also* Visual loss.
acute transient monocular, 1006
cortical, 1006
- α -blockers
contraindications to, 174t
for hypertension, 173t
side effects of, 174t
- β -blockers
for acute severe regurgitation, 80
for angina pectoris, 95
for aortic root enlargement, in Marfan
syndrome, 160
contraindications to, 174t
for heart failure, 62-63
for hypertension, 173t
with peripheral arterial disease, 160
for myocardial infarction, 105, 109
for penetrating aortic ulcers and intramural
hematoma, 162
perioperative, with noncardiac surgery,
155
side effects of, 174t
- Blood cultures
in fever of unknown origin, 840
in osteomyelitis, 906
in pneumonia, 875
- Blood flow
cerebral, 1037, 1037f
regulation of
coronary, 20
systemic, 21
- Blood gases, arterial, 202-203, 202t
in respiratory disorders, 188, 220
acute respiratory failure, 259
- Blood glucose
self-monitoring of, 660-661
tube feedings and, 686
- Blood pressure
age-dependent changes in systolic and diastolic,
176, 176f
aortic dissection and, 345
arterial, regulation of, 20
assessment of, 168-169
ambulatory, 169, 169f
in chronic kidney disease, 290
assessment of, 292
estrogen replacement therapy and, 177
myocardial ischemia and, 91
oral contraceptives, 177
orthostatic, 991-992, 992f
- Blood vessels, pulmonary, 192
- "Blue bloater", 211
- BODE index, 211-212
- Body habitus, in respiratory disorders, 187-188
- Body mass index (BMI), 252
obesity and, 675, 677-678
- Body temperature
maintenance of, in noncardiac surgery,
277
thermoregulation of, 835
- Bone. *see also* Skeleton.
health of, systemic lupus erythematosus and,
785
mass, assessments of, 758-761
normal physiology of, 732-740
peak mass of, 758
prospectus for future, 740
remodeling of, 733, 734f
types of, 733